In this free webinar, see how DPYD testing can be implemented from guidelines to go-live through practical pharmacogenomics (PGx) reporting and workflow design. The featured speakers will share ...

A prospective trial of gastrointestinal cancer patients showed the feasibility of preemptive genetic testing for DPYD/UGT1A1 variants associated with increased chemotherapy toxicity. Genotype-guided ...

Genomic medicine leverages an individual’s genetic information to guide healthcare decisions, with drug-gene testing (also known as pharmacogenomics, or PGx) being a key application that personalizes ...

A man in his early 70s died after adjuvant chemotherapy due to fulminant gastrointestinal toxicity and bowel ischaemia linked to an undetected dihydropyrimidine dehydrogenase (DPYD) deficiency, ...

Genetic testing of gastrointestinal cancer patients prior to starting chemotherapy proved feasible in a prospective study and showed a signal for a reduced risk of serious side effects. Compared with ...